News & Updates
Showing Multidisciplinary articles
Showing

Infliximab trumps other biologics as maintenance drug in CD
Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.

Oral, gut flora mainstay tied to stroke risk
A study presented at ISC 2025 shows elevated levels of Streptococcus (S.) anginosus – a type of bacteria present in the normal oral and gastrointestinal microflora – in the mouth and gut of recent stroke survivors in Japan.

Increasing obesity trajectory in midlife tied to cognitive decline, dementia
Individuals with a persistently high or an increasing pattern of general and central obesity trajectories throughout middle and late life appear to be at greater risk of cognitive decline and developing dementia, a study has shown.






